Acomplia anti-obesity medication

Acomplia is an anti-obesity medication and has been approved for marketing in European countries. The active ingredient of Acomplia is Rimonabant.
What is Acomplia:
Acomplia (rimonabant) is the first among a new category of drugs named Cannabinoid-1 and by it’s mode of action it is a Receptor blocking agent. Acomplia finds use for treatment of obesity and other related conditions.
Mode of action of Acomplia:
The mode of action of Acomplia is by causing a selective blocking of CB1 receptors, which are present in brain and peripheral organs having a role in glucose and lipid or fat breakdown into simple compounds, which include adipose tissue, the liver, gastrointestinal tract and muscles.
Acomplia by its action inhibits brain induced reactions, which make a person hungry in situations, there is smoking of canabis.
CB1 receptor blocking produced with Acomplia results into reduction of the hyperactivity of endo-cannabinoid system also known as EC system. The EC system has been described as a physiological activity of various organs influenced by the receptors like CB1 receptor.
The system has demonstrated a very vital function by regulating body weight and keeping in control of the energy balance besides glucose and lipids or fats breakdown into simple compounds, which are absorbed through small intestines for further utilization or storage in the body if the absorption is more than body requirement in a day.
Indications for Acomplia:
Acomplia is advised in combination with one’s diet and regular Physical exercise Schedule for the treatment of obesity commonly known as overweight condition of a person, who are suffering from Type 2 diabetes and having abnormal blood levels of cholesterol.
Acomplia is also helpful in preventing the dangers of cardiovascular disease.
Those patients having large waist circumference around 102 cm in men and 88 cm in women are the people who shall derive maximum benefit by use of Acomplia.
F.A.Q. of Accomplia:
Does Acomplia help in quitting of Smoking?
There is a report of a trial conducted with use of Acomplia to quit smoking involving 6500 smokers over a period of one year, there was a definite motivation in favor of quitting of smoking.
FDA has not approved use of Acomplia for quitting of smoking.
What is Status of Acomplia approval for Treatment of Obesity?
Acomplia holds approval for its use in the territories of European Union. For US markets the application is pending and approval is awaited.
Acomplia was granted approval for marketing in European Union territory in the month of June, 2006 and consequently the product was launched in July, 2006 in Britain and subsequently the product has been launched in following markets:
* Denmark
* Ireland
* Germany
* Finland
* Norway
What are the Facts regarding results of Acomplia Clinical trial studies?
The clinical studies of Acomplia have demonstrated positive improvement in very broad conditions having presence of cardiometabolic risk situations besides causing sustained weight loss.
Nearly 50 % of the patients had shown improvement in HDL-cholesterol, triglycerides and HbA1C blood levels suggesting blood sugar control in patients having received Acomplia 20mg, which was highly appreciable and was not possible without use of Accomplia.
What are the side-effects of Acomplia?
Side effects reported in a trial with Acomplia used for obesity were vomiting and nausea. About 19 percent of patients quitted the treatment as compared to 13 percent quitting by the patients taking placebo.
Conclusion:
Acomplia is the drug of choice to safely reduce weight of the persons, who are obese.

Website: http://www.buyacompliarimonabant.com/